Cell Therapy Limited entered into a non binding letter of agreement to acquire Ashington Innovation PLC in a reverse merger transaction for approximately £140 million on August 17, 2023. The transaction is subject to regulatory approvals from the FCA and shareholders approval of Ashington Innovation PLC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.275 GBX | 0.00% | 0.00% | -53.64% |
24/01 | MetalNRG's legal settlement; Impellam confirms payout | AN |
24/01 | Ashington Innovation Ends Merger Talks with Cell Therapy | MT |
1st Jan change | Capi. | |
---|---|---|
-53.64% | 10.11L | |
+107.83% | 642.66Cr | |
+98.02% | 124.97Cr | |
+2.67% | 99Cr | |
+20.03% | 78Cr | |
+2.01% | 67Cr | |
+1.44% | 59Cr | |
-.--% | 60Cr | |
+10.28% | 54Cr | |
-.--% | 50Cr |
- Stock Market
- Equities
- ASHI Stock
- News Ashington Innovation PLC
- Cell Therapy Limited entered into a non binding letter of agreement to acquire Ashington Innovation in a reverse merger transaction PLC for approximately £140 million.